Prevalence of homologous recombination deficiency (HRD)-related signatures indicates that a wider range of prostate cancer patients may benefit from PARP-inhibitor therapy
Title:
Prevalence of homologous recombination deficiency (HRD)-related signatures indicates that a wider range of prostate cancer patients may benefit from PARP-inhibitor therapy
Author:
Sztupinszki, Z. Diossy, M. Krzystanek, M. Borcsok, J. Pomerantz, M. Tisza, V. Spisak, S. Rusz, O. Csabai, I. Freedman, M. Szallasi, Z.